Charles River Laboratories (CRL)
Technical, fundamental, and sentiment analysis with recent related videos.
CRL rates Bullish overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.42); revenue is growing about 0.4% per year; net income is declining about 48.9% per year. The technical picture is bullish: price is 58.3% above the 200-day moving average; 17.5% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 80/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +0.4%. Net income 3-year avg -48.9%.
Price vs 20DMA +12.6%. RSI 73.18. Bollinger state: Above Upper Band.
Composite score 80/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Charles River’s badges diverge. The Fundamental badge is Neutral: revenue averaged +0.4 percent per year over three years while net income averaged −48.9 percent per year, a clear negative trend that leans bearish but leaves the label at Neutral. The Technical badge is Bullish, with price 12.6 percent above the 20-day moving average and the Relative Strength Index (RSI), a momentum reading, at 73.2 while price sits above the upper Bollinger Band. Sentiment is Bullish with an 80/100 composite. Two bullish signals outweigh a Neutral fundamental read, producing an overall Bullish rating.
Recent news: Coverage is broadly positive, driven by strong earnings, analyst target raises and management's 'Pathway to Purpose' guidance calling for 5–7% organic revenue growth, ~24% margins, low-double-digit EPS gains, and $300M+ of cost savings. Multiple items highlight strategic collaborations with the FDA and Labcorp to build abuse‑potential screening and behavioral‑economics tools, plus biologics QC and cGMP viral testing wins, while the stock hit a new 52‑week high and posted double‑digit jumps on the news. Sources are consistent in framing the developments as growth and margin catalysts that prompted analyst optimism and share‑price momentum.
Latest Videos
- No qualified videos yet.